09:51 AM EDT, 10/09/2024 (MT Newswires) -- NeuroSense Therapeutics ( NRSN ) said Wednesday it will seek early approval from Canadian regulators to commercialize its prospective treatment for amyotrophic lateral sclerosis, or ALS.

The move is based on "promising" results from the phase 2b testing of the company's Prime C drug candidate in patients with ALS.

The company in July released additional results from the mid-stage study showing Prime C produced a 36% reduction in disease progression and a 43% improvement in survival rates compared with patients with ALS in the placebo group.

Health Canada allows drug makers to seek conditional marketing approval in Canada for their product candidates to treat serious, life-threatening or severely debilitating diseases with a promising clinical benefit, provided the company agrees to additional testing and the prospective treatment demonstrates an acceptable safety profile.

NeuroSense shares recently were 1.2% higher shortly after Wednesday's opening bell.

Price: 1.24, Change: +0.02, Percent Change: +1.23